Canmar
5 was a
trend for a day or here to stay. This year, the Federal Court has
seen increased attempts by litigants to resolve matters more
expeditiously by way of dispositive motions. Summary judgment was
granted in three cases
6 and two
motions for default judgment were brought but dismissed based on
insufficient evidence.
ViiV Healthcare Company v. Gilead Sciences
Canada,
8 the Court held that
completion of discoveries is not a precondition to summary trial
such that resolution may be sought at very early stages of the
proceeding.
We saw the Federal Court grant summary disposition to (a)
dispose of claim construction argument,
The year 2020 was one that will not be soon forgotten, even though many of us may wish to forget! There were many interesting issues and bright spots involving R&D, innovation and IP.
To print this article, all you need is to be registered or login on Mondaq.com.
In 2019, the CJEU clarified the EU s position on
compensation for wrongly restrained defendants in IP enforcement
proceedings. What are the implications of this decision and how
does it compare with recent trends in England and
Australia?
Provisional measures in intellectual property enforcement and,
in particular, patent enforcement in the pharmaceutical industry,
have always required a careful balancing act between the interests
of the rights-holder and the interests of the alleged
infringer.
This is because, at an early stage in proceedings, the court is
required to consider restraining an alleged infringer from certain
A Seattle-based company on Tuesday sued telecommunications giant AT&T for $1.35 billion, alleging the company stole its patented “twinning” technology that allows multiple devices to respond to the same phone nu
BioArctic receives European patent for new antibodies targeting Alzheimer s disease
STOCKHOLM, Jan. 27, 2021 /PRNewswire/
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aß) and are linked to the company s project AD1503. The patent enters into force on 27 January 2021 and expires in 2030.
BioArctic s newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid beta. Monomers of pE3-Ab are highly prone to aggregate, leading to the formation of harmful soluble Ab aggregates which cause debilitating cognitive and other symptoms in Alzheimer s disease.